temozolomide has been researched along with Lymphoma, Non-Hodgkin in 16 studies
Lymphoma, Non-Hodgkin: Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 5.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| "Temozolomide (TMZ) is an oral alkylating agent with significant activity against glioblastoma multiforme (GBM) and melanoma." | 3.75 | Non-Hodgkin lymphoma following temozolomide. ( Das, P; Dwary, A; Goyal, S; Gupta, D; Mohanti, BK; Muzumder, S; Sharma, A; Thulkar, S, 2009) |
| "Glioblastoma multiforme is an astrocyte-derived tumour representing the most aggressive primary brain malignancy." | 1.51 | Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme. ( Aleixo, GF; Batalini, F; Drews, R; Kaufmann, MR, 2019) |
| "Temozolomide (TMZ) has established antineoplastic activity in the central nervous system in other disease states, with a favorable toxicity profile." | 1.51 | Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma. ( Brenner, A; Butler, MJ; Faivre, G; Le, I, 2019) |
| "The temozolomide was stopped and the lymphoma was successfully treated with chemotherapy." | 1.38 | Non-Hodgkin's lymphoma in a patient on treatment with temozolomide. ( Otty, Z; Sabesan, S, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 9 (56.25) | 24.3611 |
| 2020's | 2 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Kaulen, LD | 1 |
| Baehring, JM | 1 |
| Wang, H | 1 |
| Wang, M | 1 |
| Wei, J | 1 |
| Wang, L | 1 |
| Mao, L | 1 |
| Jin, J | 1 |
| Zheng, J | 1 |
| Wang, C | 1 |
| Liu, F | 1 |
| Li, X | 1 |
| Xu, X | 1 |
| Chen, K | 1 |
| Wu, H | 1 |
| Wang, Y | 2 |
| Yang, S | 1 |
| Wang, K | 1 |
| Chen, C | 1 |
| Sun, P | 1 |
| Cui, J | 1 |
| Yan, S | 1 |
| Chen, H | 1 |
| Xia, Y | 1 |
| Bi, X | 1 |
| Liu, P | 1 |
| Yang, H | 1 |
| Nie, M | 1 |
| Zhang, XW | 1 |
| Jiang, W | 1 |
| Li, ZM | 1 |
| Batalini, F | 1 |
| Kaufmann, MR | 1 |
| Aleixo, GF | 1 |
| Drews, R | 1 |
| Faivre, G | 1 |
| Butler, MJ | 1 |
| Le, I | 1 |
| Brenner, A | 1 |
| Pulczynski, EJ | 1 |
| Kuittinen, O | 1 |
| Erlanson, M | 1 |
| Hagberg, H | 1 |
| Fosså, A | 1 |
| Eriksson, M | 1 |
| Nordstrøm, M | 1 |
| Østenstad, B | 1 |
| Fluge, Ø | 1 |
| Leppä, S | 1 |
| Fiirgaard, B | 1 |
| Bersvendsen, H | 1 |
| Fagerli, UM | 1 |
| Broes, K | 1 |
| Van Ginderachter, L | 1 |
| Joosens, E | 2 |
| Maes, A | 1 |
| Theunissen, K | 1 |
| Schepers, S | 1 |
| Deben, K | 1 |
| Claes, J | 1 |
| Mebis, J | 1 |
| Cox, T | 1 |
| Neyns, B | 1 |
| Cordera, S | 1 |
| Pouratian, N | 1 |
| Nader, P | 1 |
| Sharma, A | 1 |
| Gupta, D | 1 |
| Mohanti, BK | 1 |
| Thulkar, S | 1 |
| Dwary, A | 1 |
| Goyal, S | 1 |
| Muzumder, S | 1 |
| Das, P | 1 |
| Otty, Z | 1 |
| Sabesan, S | 1 |
| Osmani, AH | 1 |
| Masood, N | 1 |
| Herrlinger, U | 1 |
| Hebart, H | 1 |
| Kanz, L | 1 |
| Dichgans, J | 1 |
| Weller, M | 1 |
| Woll, PJ | 1 |
| Crowther, D | 1 |
| Johnson, PW | 1 |
| Soukop, M | 1 |
| Harper, PG | 1 |
| Harris, M | 1 |
| Brampton, MH | 1 |
| Newlands, ES | 1 |
| Reni, M | 1 |
| Ferreri, AJ | 1 |
| Landoni, C | 1 |
| Villa, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Immunochemotherapy in Primary Central Nervous System Lymphoma With Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Ifosfamide, Vincristine, Vindesine, Temozolomide and DepoCyte Induction Followed by Maintenance Treatment in Elderly Patients With Temozolomi[NCT01458730] | Phase 2 | 66 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Phase II Study of Gamma Knife Radiosurgery and Temozolomide (Temodar) for Newly Diagnosed Brain Metastases[NCT00582075] | Phase 2 | 25 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00582075)
Timeframe: 2 years
| Intervention | weeks (Median) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 31 |
Patients developing distant brain failure (DBF) at one year. An approximation method was used to arrive at the reported percentage. (NCT00582075)
Timeframe: 1 years
| Intervention | percentage of participants (Number) |
|---|---|
| Radiosurgery 15-24 Gy + Adjuvant Temozolomide | 37 |
1 review available for temozolomide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Treatment Options for Recurrent Primary CNS Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms | 2022 |
2 trials available for temozolomide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Successful change of treatment strategy in elderly patients with primary central nervous system lymphoma by de-escalating induction and introducing temozolomide maintenance: results from a phase II study by the Nordic Lymphoma Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2015 |
Phase II trial of temozolomide in low-grade non-Hodgkin's lymphoma.
Topics: Adult; Aged; Antineoplastic Agents; Dacarbazine; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle | 1995 |
13 other studies available for temozolomide and Lymphoma, Non-Hodgkin
| Article | Year |
|---|---|
Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Child | 2018 |
Stereotactic Brachytherapy with Iodine-125 Seeds Plus Temozolomide Induced Complete and Durable Remission in a Patient with Recurrent Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Brachytherapy; Central Nervous System Neoplasms; Combined Modalit | 2018 |
miR-370 Sensitizes TMZ Response Dependent of MGMT Status in Primary Central Nervous System Lymphoma.
Topics: Antineoplastic Agents, Alkylating; Central Nervous System Neoplasms; DNA Modification Methylases; DN | 2020 |
High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Femal | 2019 |
Temozolomide-induced aplastic anaemia and incidental low-grade B-cell non-Hodgkin lymphoma in a geriatric patient with glioblastoma multiforme.
Topics: Aged, 80 and over; Anemia, Aplastic; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Fata | 2019 |
Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Disea | 2019 |
Secondary non-Hodgkin lymphoma of the ethmoid sinus after temozolomide.
Topics: Antineoplastic Agents, Alkylating; Dacarbazine; Ethmoid Sinus; Humans; Lymphoma, Non-Hodgkin; Male; | 2015 |
Non-Hodgkin's lymphoma in patients with glioma treated with temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dacarbaz | 2008 |
Non-Hodgkin lymphoma following temozolomide.
Topics: Adult; Antineoplastic Agents, Alkylating; Dacarbazine; Female; Glioblastoma; Humans; Lymphoma, Non-H | 2009 |
Non-Hodgkin's lymphoma in a patient on treatment with temozolomide.
Topics: Aged; Antineoplastic Agents, Alkylating; Cerebellar Neoplasms; Chemoradiotherapy; Dacarbazine; Gliob | 2012 |
Temozolomide for relapsed primary CNS lymphoma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Central Ne | 2012 |
Relapse of primary CNS lymphoma after more than 10 years in complete remission.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Mo | 2005 |
Salvage therapy with temozolomide in an immunocompetent patient with primary brain lymphoma.
Topics: Aged; Antineoplastic Agents, Alkylating; Brain Neoplasms; Dacarbazine; Humans; Immunocompetence; Lym | 2000 |